表紙
市場調查報告書

胰島素筆針型注射器的全球市場:各產品類型 、各流通管道,各用途,各地區的趨勢分析,市場佔有率,預測:2016年-2026年

Global Insulin Pen Market by Product Type, By Distribution Channel, By Application, By Region ; Trend Analysis, Competitive Market Share & Forecast, 2016-26

出版商 Blueweave Consulting & Research Private Limited 商品編碼 948285
出版日期 內容資訊 英文 186 Pages
商品交期: 最快1-2個工作天內
價格
胰島素筆針型注射器的全球市場:各產品類型 、各流通管道,各用途,各地區的趨勢分析,市場佔有率,預測:2016年-2026年 Global Insulin Pen Market by Product Type, By Distribution Channel, By Application, By Region ; Trend Analysis, Competitive Market Share & Forecast, 2016-26
出版日期: 2020年04月01日內容資訊: 英文 186 Pages
簡介

全球胰島素筆針型注射器市場,預計從2019年的43億美元擴大到2026年78億美元,從2020年到2026年的年複合成長率預計為8.8%。胰島素筆針型注射器,20多年前首次發售,比使用注射器和管瓶在實用性面有很大的優點而廣泛普及。

本報告提供全球胰島素筆針型注射器市場調查,彙整產業的考察,市場概要,各地區市場分析,主要企業的簡介等資訊。

目錄

第1章 調查架構

第2章 調查手法

第3章 摘要整理

第4章 產業的考察

  • 產業的價值鏈分析
  • DROC分析
    • 成長促進因素
    • 成長阻礙因素
    • 市場機會
    • 課題
  • 技術方面情勢/最新趨勢
  • 各公司的市場佔有率分析
  • 波特的五力分析
    • 供應商談判力
    • 買主談判力
    • 新加入廠商勢力的威脅
    • 替代品的威脅
    • 企業間的競爭

第5章 全球市場概要

  • 市場規模與預測:2016∼2026
  • 市場佔有率與預測
    • 各產品類型
      • 拋棄式
      • 可重複使用
    • 各流通管道
      • 線上藥局
      • 醫院藥局
      • 零售藥局
      • 糖尿病診所
    • 各用途
      • 第一型糖尿病
      • 第二型糖尿病
    • 各地區
      • 北美
      • 歐洲
      • 亞太地區
      • 南美
      • 中東、非洲

第6章 北美市場

  • 市場規模與預測:2016∼2026
  • 市場佔有率與預測
  • 各產品類型
  • 各流通管道
  • 各用途
  • 各國
    • 美國
    • 加拿大

第7章 歐洲市場

  • 市場規模與預測:2016∼2026
  • 市場佔有率與預測
  • 各產品類型
  • 各流通管道
  • 各用途
  • 各國
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他歐洲

第8章 亞太地區市場

  • 市場規模與預測:2016∼2026
  • 市場佔有率與預測
  • 各產品類型
  • 各流通管道
  • 各用途
  • 各國
    • 中國
    • 印度
    • 日本
    • 其他

第9章 南美市場

  • 市場規模與預測:2016∼2026
  • 市場佔有率與預測
  • 各產品類型
  • 各流通管道
  • 各用途
  • 各國
    • 巴西
    • 墨西哥
    • 阿根廷
    • 其他

第10章 中東和非洲市場

  • 市場規模與預測:2016∼2026
  • 市場佔有率與預測
  • 各產品類型
  • 各流通管道
  • 各用途
  • 各國
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 其他

第11章 企業簡介 (公司概要,財務矩陣,主要的產品狀況,主要人物,主要的競爭企業,聯絡原住所,策略性展望)*

  • B. Braun Melsungen AG
  • Eli Lilly and Company
  • Artsana S.p.A.
  • Novo Nordisk A/S
  • Owen Mumford Ltd.
  • TERUMO CORPORATION
  • HTL-Strefa
  • Companion Medical
  • Berlin-Chemie Ag
  • Pendiq Gmbh
  • Emperra GmbH E-Health Technologies
  • Ypsomed Ag
  • Sanofi
  • Digital Medics
  • Diamesco
  • Gerresheimer AG
  • Companion Medical
  • Biocon
  • Jiangsu Delfu medical device Co.
  • Lantus
  • Other prominent players
目錄
Product Code: BWC20010

Title:
Global Insulin Pen Market by Product Type (Disposable, Reusable), By Distribution Channel (Online Pharmacies, Hospital Pharmacies, Retail Pharmacies, diabetes Clinics), By Application (Type 1 Diabetes, Type 2 Diabetes), By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa); Trend Analysis, Competitive Market Share & Forecast, 2016-26.

The Global Insulin Pen Market valued USD 4300 million in 2019, and projected to reach USD 7800 million by 2026, at a CAGR of 8.8% during the forecast period 2020-2026. Insulin is necessary for the management of type 1 diabetes and is more commonly used for the medication of type 2 diabetes. The insulin pen was first launched over 20 years ago and has evolved to provide significant working advantages compared with the syringe and vial. Insulin Pen devices are now used by patients with diabetes globally, but there are marked geographic differences in the use of reusable and disposable pens. In many countries, syringe and vial are still the most popular method of delivering insulin, whereas, in many countries, the use of reusable or disposable pens is more common. Diabetes is an endocrine health problem that causes high levels of sugar in the blood. For diabetic patients, blood sugar must be monitored carefully using a glucometer. If insulin is necessary to be injected in order to regulate the activity of the pancreas, this can be accomplished using insulin injection pens, either pre-filled disposable or refillable. This allows for light and easy use while providing accurate information on the dose. These factors are expected to propel the insulin pen market growth during the forecast period.

An electronic insulin pen was designed for diabetic patient's dependent on insulin use in order to prevent wrong timing and wrong dosage caused by old age, vision, or mental illness. The insulin pen can be used electronically for routine dose injections and was designed to be able to used manually in the emergency. It is aimed that the patient can set the dose easily by using the fairly simple menu of the device. Additionally, the device was not designed as disposable, and the device was designed as reusable by changing the insulin tube. Because the tube chamber was designed to be suitable for all types of insulin, it can be used by changing the tube without using a different pen. Dose accuracy was adjusted with a low error by performing insulin dose measurements on a sensitive balance.

Increasing prevalence of diabetes is expected to drive the global insulin pen market

Diabetes is a metabolic disorder in both the developed and developing countries. It is expected that about 371 million people have disease worldwide and this number has been estimated to rise up to 552 million by 2030. The rate of prevalence of diabetes is high in Asian countries. About 92.3 and 63 million people in China and India suffer from this metabolic disorder respectively. Diabetes (T2D) reduces the life expectancy by 5-10 years. Prevalence of diabetes is rapidly increasing worldwide due to interactions between environmental factors, genetic factors and lifestyle. Furthermore, factors such as population growth, urbanization, aging, and increasing prevalence of obesity and physical inactivity are significantly contributing to the increasing global burden of diabetics. This is the major growth driver for the global insulin pen market.

Ease of use is expected to the drive the market growth of global insulin pen market

The insulin pen offers better convenience, flexibility, and quality of life results with pen devices as compared to the conventional insulin delivery devices.6 Dose accuracy with insulin pens was also reported to be better in many studies in comparison to vials and syringes method, especially at low doses (≤5 IU). All these factors are essential in improving patient adherence to the treatment and also reducing hypoglycemic episodes.

Reusable Insulin pen segment is expected to dominate the market during the forecast period

With individual use of the pen device, the prospect of infection is decreased. Examples of such reusable insulin pens are Humapen® (for both human and analog insulins), NovoPen® 3 (for both human and analog insulins), Autopen® pen, Optipen®, and Wosulin pen. HumaPen® MEMOIR(TM) comes with a memory allowing diabetes patients, especially those on multiple mealtime doses, to record and examine their last 16 insulin doses. Insulin pens have shown dose accuracy before and after simulation of 5 years of use across a broad range of temperature and humidity conditions and after mechanical challenges.

These factor help the global insulin market growth during the forecast period.

North America expected to witness significant growth in the market during the forecast period

Insulin medication is deemed to be the center for the treatment of people who have diabetes, and in the United States, the adoption of insulin pens is increasing significantly as compared to the needles and syringes during the forecast period.

Asia-Pacific is also estimated to grow at a high CAGR during the forecast period due to the high population in China, India, and other Asian countries.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Research Methodology

  • 2.1. Qualitative Research
    • 2.1.1. Primary & Secondary Sources
  • 2.2. Quantitative Research
    • 2.2.1. Primary & Secondary Sources
  • 2.3. Breakdown of Primary Research Respondents, By Region
    • 2.3.1. Secondary Research
    • 2.3.2. Primary Research
  • 2.4. Breakdown of Primary Research Respondents
  • 2.5. Market Size Estimation
  • 2.6. Assumption for the Study
  • 2.7. Market Breakdown & Data Triangulation

3. Executive Summary

4. Global Insulin Pen Industry Insights

  • 4.1. Industry Value Chain Analysis
  • 4.2. DROC Analysis
    • 4.2.1. Growth Drivers
    • 4.2.2. Restraints
    • 4.2.3. Opportunities
    • 4.2.4. Challenges
  • 4.3. Technological Landscape/Recent Development
  • 4.4. Company Market Share Analysis, 2019
  • 4.5. Porter's Five Forces Analysis
    • 4.5.1. Bargaining Power of Suppliers
    • 4.5.2. Bargaining Power of Buyers
    • 4.5.3. Threat of New Entrants
    • 4.5.4. Threat of Substitutes
    • 4.5.5. Intensity of Rivalry

5. Global Insulin Pen Market Overview

  • 5.1. Market Size & Forecast by Value, 2016-2026
    • 5.1.1. By Value (USD Billion)
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type
      • 5.2.1.1. Disposable
      • 5.2.1.2. Reusable
    • 5.2.2. By Distribution Channel
      • 5.2.2.1. Online Pharmacies
      • 5.2.2.2. Hospital Pharmacies
      • 5.2.2.3. Retail Pharmacies
      • 5.2.2.4. Diabetes Clinics
    • 5.2.3. By Application
      • 5.2.3.1. Type 1 Diabetes
      • 5.2.3.2. Type 2 Diabetes
    • 5.2.4. By Region
      • 5.2.4.1. North America
      • 5.2.4.2. Europe
      • 5.2.4.3. Asia Pacific
      • 5.2.4.4. Latin America
      • 5.2.4.5. Middle East & Africa

6. North America Insulin Pen Market

  • 6.1. Market Size & Forecast by Value, 2016-2026
    • 6.1.1. By Value (USD Billion)
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Application
    • 6.2.4. By Country
      • 6.2.4.1. United States
      • 6.2.4.2. Canada

7. Europe Insulin Pen Market

  • 7.1. Market Size & Forecast by Value, 2016-2026
    • 7.1.1. By Value (USD Billion)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Application
    • 7.2.4. By Country
      • 7.2.4.1. Germany
      • 7.2.4.2. United Kingdom
      • 7.2.4.3. France
      • 7.2.4.4. Italy
      • 7.2.4.5. Spain
      • 7.2.4.6. Rest of Europe

8. Asia Pacific Insulin Pen Market

  • 8.1. Market Size & Forecast by Value, 2016-2026
    • 8.1.1. By Value (USD Billion)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Application
    • 8.2.4. By Country
      • 8.2.4.1. China
      • 8.2.4.2. India
      • 8.2.4.3. Japan
      • 8.2.4.4. Rest of Asia Pacific

9. Latin America Insulin Pen Market

  • 9.1. Market Size & Forecast by Value, 2016-2026
    • 9.1.1. By Value (USD Billion)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By Distribution Channel
    • 9.2.3. By Application
    • 9.2.4. By Country
      • 9.2.4.1. Brazil
      • 9.2.4.2. Mexico
      • 9.2.4.3. Argentina
      • 9.2.4.4. Rest of Latin America

10.Middle East & Africa Insulin Pen Market

  • 10.1. Market Size & Forecast by Value, 2016-2026
    • 10.1.1. By Value (USD Billion)
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By Distribution Channel
    • 10.2.3. By Application
    • 10.2.4. By Country
      • 10.2.4.1. Saudi Arabia
      • 10.2.4.2. UAE
      • 10.2.4.3. South Africa
      • 10.2.4.4. Rest of Middle East & Africa

11.Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook) *

  • 11.1. B. Braun Melsungen AG
  • 11.2. Eli Lilly and Company
  • 11.3. Artsana S.p.A.
  • 11.4. Novo Nordisk A/S
  • 11.5. Owen Mumford Ltd.
  • 11.6. TERUMO CORPORATION
  • 11.7. HTL-Strefa
  • 11.8. Companion Medical
  • 11.9. Berlin-Chemie Ag
  • 11.10. Pendiq Gmbh
  • 11.11. Emperra GmbH E-Health Technologies
  • 11.12. Ypsomed Ag
  • 11.13. Sanofi
  • 11.14. Digital Medics
  • 11.15. Diamesco
  • 11.16. Gerresheimer AG
  • 11.17. Companion Medical
  • 11.18. Biocon
  • 11.19. Jiangsu Delfu medical device Co.
  • 11.20. Lantus
  • 11.21. Other prominent players